CAS: 1370256-78-2

SKLB4771

SKLB4771 (FLT3-IN-1) is a novel potent and selective Flt3 inhibitor.

SKLB4771 (FLT3-IN-1) is a selective small molecule inhibitor predominantly known for targeting FLT3, a receptor tyrosine kinase implicated in various hematological malignancies. Originating from a structure-based design and optimization process, this compound functions by competitively inhibiting the ATP-binding site of FLT3, thereby obstructing its autophosphorylation and subsequent downstream signaling cascades. The primary mechanism of action for SKLB4771 involves the interruption of FLT3-driven proliferative and survival pathways, making it a valuable tool in probing the molecular underpinnings of FLT3-dependent cancers, such as acute myeloid leukemia (AML). In preclinical studies, SKLB4771 has demonstrated efficacy in abrogating FLT3 signaling, leading to the suppression of leukemic cell proliferation and the induction of apoptosis. Its application extends to the exploration of FLT3-related oncogenic processes, aiding in the development of targeted therapeutic strategies. Further research on SKLB4771 may facilitate the advancement of novel interventions in FLT3-associated malignancies.